Our diagnostic solutions 


The only molecular profiling combining liquid and solid biopsies

Sample type:


Turnaround time:

Solid & liquid biopsy

- 1 block or 25 slides

- 2 blood samples

10 working days

Scroll down to discover

OncoSTRAT&GO screens the tumors much beyond the usual suspects

A unique combination of analyses for treatment decision

This solution is an integrated approach that combines the analyses of a solid biopsy (by next-generation sequencing (313 genes), IHCs and additional tests) with the analysis of a blood biopsy. The blood profiling focuses either on the circulating tumor DNA (for deciphering tumor heterogeneity) or in DNA from blood cells (for studying specific germline gene alterations related to BRCAness phenotype that are challenging to detect in FFPE samples).

OncoSTRAT&GO establishes a complete genetic profile of the tumor, which can be used to identify sensitivity or resistance to targeted therapies, chemotherapies and immunotherapies.

Sample Type:

Solid and liquid biopsy

Recommended for:

  • The following stage IV solid tumors in adults:
    - Non-small cell lung cancer
    - HR+, HER2+ and triple-negative breast cancer
    - Colorectal cancer
    - Cancer of unknown primary
    - Ovarian cancer
    - Pancreatic cancer
    - Prostate cancer

Gene panel:

313 genes for the solid biopsy

Number of genes for the liquid biopsy variable depending on the cancer type 


  • • 1 block or 25 slides (5 μm on SuperFrost Plus)
  • • 1 blood sample (1x10 ml Streck tube or 1x10 ml EDTA tube)

Turnaround time:

10 working days

Order a solution DOWNLOAD BROCHURE

Why combine DNA, RNA and protein analyses?

An unique immunogram for immunotherapy selection

Our immunogram is created based on 5 key points, PD-L1 % (FDA) , TMB (ASCO 2017) (12), CD8 T-cell infiltrate (ASCO 2017), MSI(FDA) and Sensitivity/Resistance mutations (ASCO 2017)(13). With those tools, we are able to give you a clear vision of the potential clinical response of your patient.

OncoSTRAT&GO clinical evidences

case studies

Practical details

Ordering a solution is very simple: Just log on to OncoSHARE and select your solution(s). If you don’t have a kit, we’ll send you one. After interpretation by our expert team an interactive report will be available for you on OncoSHARE . You can review, edit and/or share it.

A comprehensive and integrated report will be available trhough the OncoSHARE platform. After 7 to 10 days, depending on the test you purchased, the analysis report will be available. In a simple and interactive manner, it will guide you in selecting the most appropriate treatment based on the unique signature of the tumor.

For more information about the price in your country please contact the sales department at sales@oncodna.com

If your question is not addressed above and/or if you would like more information about our solutions, please contact us at infos@oncodna.com our Patient and Scientific Support teams are available to answer your questions directly from Monday to Friday. You can also reach us through the chat (icon in the bottom right corner of the window).

Other solutions we have developed for your needs

Complete solution integrating the analysis of solid and liquid biopsies

OncoDEEP analyses solid biopsies by combining nextgeneration sequencing (313 genes), IHCs to study protein expression and additional tests. This complete tumor profiling allows to predict patient response to approved or experimental targeted drugs, immunotherapies and chemotherapies. The NGS panel is accurately designed according to oncologists’ needs in their current practice. Importantly, it also includes an accurate determination of MSI, TMB and LOH. The NGS panel is regularly updated based on new findings reported in literature in order to provide patients with the most cost-effective solution.

Read more
Smart and cost-effective liquid biopsy panels with selected key genes per tumor type

OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample. It is the perfect solution to identify therapeutic options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can be used as a tool to detect treatment resistance to targeted therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as for monitoring cancer progression.

Read more
Personalized liquid biopsy for patients monitoring

OncoTRACE by OncoDNA is a test based on circulating tumor DNA (ctDNA) in liquid biopsies (principally blood). It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.

This assay is customized for each patient, as it contains personal cancer-specific markers and variants identified in a previous genomic analysis.

In 2013 OncoDNA became the first company to personalise a specific OncoTRACE test for every patient (a recent publication in 2017 in Nature demonstrates the efficacy of such an approach). Chrisie et al Journal of Clinical Oncology 35, no. 12 (April 20, 2017) 1274-1280.

Read more